Figure 3

In vivo anti-lymphoma activities HX009 in three different types of preclinical lymphoma models (Table 1) as presented by the tumor growth inhibition curves (A–D), and the expression correlations among the immune checkpoints, CD47, CD274 (encoding PD-L1) and PD-L2 genes in DLBCL (E). Tumor growth was measured twice a week and is shown as average tumor size per group ± SEM. Statistical significance was determined by one-way ANOVA. Gene expression correlations at mRNA levels measured by RNAseq (log2(TPM). TPM represents "Transcripts Per Kilobase Million" and the correlation at protein levels measured by IHC-H-scores. (A) Human Raji-B-lymphoma xenograft model (The treatment TGI values were displayed next to the curve; G2: HX009 group and G3: SIRPα-Fc group); (B) Human Karpas-299 T-lymphoma xenograft (“MiXeno”) model (G2: HX008 group, G3: HX009-3 mg/kg group, G4: HX009-10 mg/kg group, G5: HX009-30 mg/kg group); (C) Humanized mouse syngeneic A20-B lymphoma model (HuGEMM PD-L1 × PD1 × CD47 × SIRPα) (G2: HX009 group and G3: HX008 group, and G4: SIRPα-Fc group); (D) A representative lymphoma PDX (G2: HX009 group and G3: CHOP group); (E) Correlation of the CD47, PD-L1 and PD-L2 mRNAs levels among the DLBCL-PDXs, the corresponding R-values/p-values are displayed in the figure, p-values: ***:0–0.001, **: 0.001–0.01, *: 0.01–0.05.